Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study
Authors:
- Carole CumminsCCCarole Cummins
- Satyam KumarSKSatyam Kumar
- Joanna LongJLJoanna Long
- Janos BalegaJBJanos Balega
- Tim BroadheadTBTim Broadhead
- Timothy DuncanTDTimothy Duncan
- Richard J. EdmondsonRERichard J. Edmondson
- Christina FotopoulouCFChristina Fotopoulou
- Rosalind M. GlasspoolRGRosalind M. Glasspool
- Desiree KolomainenDKDesiree Kolomainen
- Simon LeesonSLSimon Leeson
- Ranjit ManchandaRanjit Manchanda
Open Access
Abstract
We investigated URS and impact on survival in whole patient cohorts with AOC treated within gynaecological cancer centres that participated in the previously presented SOCQER 2 study. National cancer registry datasets were used to identify FIGO Stage 3,4 and unknown stage patients from 11 cancer centres that had previously participated in the SOCQER2 study. Patient outcomes’ association with surgical ethos were evaluated using logistic regression and Cox proportional hazards. Centres were classified into three groups based on their surgical complexity scores (SCS); those practicing mainly low complexity, (5/11 centres with >70% low SCS procedures, 759 patients), mainly intermediate (3/11, 35–50% low SCS, 356 patients), or mainly high complexity surgery (3/11, >35% high SCS, 356 patients). Surgery rates were 43.2% vs. 58.4% vs. 60.9%. across mainly low, intermediate and high SCS centres, respectively, p < 0.001. Combined surgery and chemotherapy rates were 39.2% vs. 51.8% vs. 38.3% p < 0.000 across mainly low, intermediate and high complexity groups, respectively. Median survival was 23.1 (95% CI 19.0 to 27.2) vs. 22.0 (95% CI 17.6 to 26.3) vs. 17.9 months (95% CI 15.7 to 20.1), p = 0.043 in mainly high SCS, intermediate, and low SCS centres, respectively. In an age and deprivation adjusted model, compared to patients in the high SCS centres, patients in the low SCS group had an HR of 1.21 (95% CI 1.03 to 1.40) for death. Mainly high/intermediate SCS centres have significantly higher surgery rates and better survival at a population level. Centres that practice mainly low complexity surgery should change practice. This study provides support for the utilization of URS for patients with advanced OC.Keywords
Funding Information
- National Institute for Health and Care Excellence
This publication has 23 references indexed in Scilit:
- British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practiceEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2017
- Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based studyGynecologic Oncology, 2017
- The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancerArchives of Gynecology and Obstetrics, 2016
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialThe Lancet, 2015
- Ovarian cancer in the United States: Contemporary patterns of care associated with improved survivalGynecologic Oncology, 2015
- Surgical practice of UK gynaecological oncologists in the treatment of primary advanced epithelial ovarian cancer (PAEOC): A questionnaire surveyGynecologic Oncology, 2013
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009
- Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2007
- Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approachGynecologic Oncology, 2004
- Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-AnalysisJournal of Clinical Oncology, 2002